title: Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies.
abstract: OBJECTIVE
  Lafutidine, an antagonist of histamine H2-receptor, has gastroprotective activity associated with activation of capsaicin-mediated sensory nerves. The objective of this study was to investigate the efficacy of lafutidine for the treatment of taxane-induced peripheral neuropathy in patients with gynecological malignancies.
  
  
  METHODS
  Twenty patients with taxane-induced peripheral neuropathy during the treatment of gynecological malignancy were enrolled in this study. After obtaining their informed consent, lafutidine (20mg per day) was administered orally, the efficacy of which was assessed according to the Patient Neurotoxicity Questionnaire item 1.
  
  
  RESULTS
  Significant, moderate, slight, and no effects were observed in four, five, five, and six patients, respectively. The efficacy including significant and moderate effect was observed in nine (45%) of the 20 patients (95% confidence interval, 25.8%-65.8%). No adverse effects due to lafutidine were observed.
  
  
  CONCLUSIONS
  This pilot study supports the relatively high efficacy of lafutidine for the treatment of taxane-induced peripheral neuropathy. Further prospective studies are warranted.
authors: Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo 116-8567, Japan. naganoog@dnh.twmu.ac.jp
authors: Hiroaki
authors: H
authors: Nagano
authors: Hideomi
authors: H
authors: Sanai
authors: Mitsue
authors: M
authors: Muraoka
authors: Koichiro
authors: K
authors: Takagi
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D010880:Piperidines / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; D043823:Taxoids; C080625:taxane; C076948:lafutidine